Aerosolizable lipid nanoparticles (LNPs) are designed for efficient pulmonary delivery of nucleic acids like mRNA. Featuring novel lipids, they ensure stability during nebulization, target lung cells effectively, and enhance gene delivery for treating lung diseases.
Messenger RNA (mRNA) therapeutics hold immense promise for treating a wide range of pulmonary diseases, including genetic disorders like cystic fibrosis and various infections. Lipid nanoparticles (LNPs) have emerged as a leading platform for delivering these nucleic acids, demonstrating success in systemic applications. Local pulmonary delivery via aerosolization offers significant advantages, such as achieving higher therapeutic concentrations directly in the lungs while minimizing systemic side effects, making it a highly desirable approach for lung-specific conditions.
Despite this potential, current LNP formulations face substantial challenges for effective pulmonary administration. Existing LNPs are primarily designed for systemic delivery, often targeting the liver, and are not optimized for lung-specific applications. Aerosolization itself poses a significant hurdle, as the shear forces generated during the process can degrade sensitive mRNA cargo and destabilize the LNP structures. Furthermore, achieving efficient deposition of particles in therapeutically relevant lung regions, ensuring adequate cellular uptake and endosomal escape within lung epithelial cells, and overcoming biological barriers like mucus penetration and clearance by alveolar macrophages remain critical unresolved issues, leading to limited clinical efficacy in prior attempts.
These pharmaceutical compositions comprise aerosolizable lipid nanoparticles (LNPs) engineered for pulmonary delivery of biologically active nucleic acids, primarily messenger RNA. Each LNP is formulated with novel cationic ionizable lipids (CILs) featuring a distinct chemical formula, alongside phospholipids, PEGylated lipids, and sterols, encapsulating the nucleic acid cargo. Optimized for vibrating mesh nebulizers, these LNPs maintain integrity and nucleic acid stability post-nebulization, exhibiting precise physical properties like 50-150 nm particle size and high encapsulation efficiency. Their aerodynamic characteristics ensure efficient deposition in therapeutically relevant lung regions, leading to superior transfection efficiency in lung epithelial cells, attributed to the unique CIL structure which also facilitates improved endosomal escape.
This technology is differentiated by overcoming challenges in pulmonary nucleic acid delivery, particularly for mRNA, which often suffers from aerosolization instability and poor lung targeting. Its core distinction lies in the novel cationic ionizable lipids, whose unique chemical structure enhances nebulization stability, cellular uptake, and endosomal escape in lung epithelial cells. This results in superior gene delivery and higher lung transfection efficiency compared to existing LNP formulations. Furthermore, these compositions exhibit exceptional aerodynamic properties, ensuring efficient and targeted deposition within the lungs, a critical advantage over less optimized or systemically-focused delivery systems.
These are aerosolizable lipid nanoparticles for pulmonary delivery of nucleic acids like mRNA. They comprise novel cationic ionizable lipids, phospholipids, PEGylated lipids, and sterols, optimized for nebulization. Their precise structure ensures stability, efficient lung deposition, and superior transfection into lung epithelial cells, enabling targeted therapy for respiratory conditions.
DOI: https://doi.org/10.1002/btm2.10580